Evicenter
Eliquis (apixaban) in Nonvalvular atrial fibrillation
Manufacturer
Bristol-Myers Squibb Company; Pfizer Inc
Prescribing information
Eliquis (opens in a new tab)
Questions
59
Last updated

All questions

Real-world evidence: Eliquis (apixaban) in nonvalvular atrial fibrillation

4 questions · 4 sources

Real-world evidence

Eliquis vs Xarelto (rivaroxaban): is there real-world evidence in atrial fibrillation?

Note: The statement that no clinical trial results compare Eliquis with Xarelto for stroke risk reduction is the manufacturer's, as captured on November 12, 2026.

Eliquis vs Xarelto in adults 65 and older: what did real-world data show (Dawwas 2025)?

Eliquis vs Xarelto in adults younger than 65: what did FDA Sentinel data show?

Is switching from Eliquis to Xarelto linked to more stroke or bleeding (ATHENS)?

Note: The hazard ratios compare patients who switched from Eliquis to Xarelto with patients who continued Eliquis; in the leave-behind charts, switchers had the higher incidence (stroke/SE 1.53 vs 0.75, major bleeding 4.59 vs 2.44 per 100 person-years).